2-Arachidonoylglycerol (2-AG)
An endogenous cannabinoid — not a terpene — that activates the same receptors as THC and shapes how cannabis affects the brain.
Heads up: 2-AG is not a terpene. It's an endocannabinoid — a lipid signaling molecule your own body makes. The article generator slotted it into the terpene template, but the honest thing to do is correct that. 2-AG matters to cannabis because it binds the same CB1 and CB2 receptors that THC hijacks. If you came here looking for an aroma compound, you want [Myrcene](myrcene) or [Limonene](limonene) instead.
A note on classification
This article was requested under a 'terpene' template, but 2-arachidonoylglycerol is not a terpene. Terpenes are volatile hydrocarbons built from isoprene units that give plants their aroma. 2-AG is a monoacylglycerol — a glycerol backbone esterified to arachidonic acid, a 20-carbon polyunsaturated fatty acid Strong evidence. It belongs to the family of endocannabinoids: lipid signaling molecules produced on demand by animal cells [1][2]. We're keeping the article because the topic is foundational to cannabis pharmacology, but the standard terpene fields (aroma, boiling point, strains high in it) don't apply.
What 2-AG is
2-AG was identified as an endogenous cannabinoid receptor ligand in 1995 by two independent groups working in Japan and Israel [1][2]. Along with anandamide (N-arachidonoylethanolamine, or AEA), it is one of the two best-characterized endocannabinoids in mammals Strong evidence.
Key facts:
- Structure: glycerol + arachidonic acid joined by an ester bond at the sn-2 position.
- Synthesis: produced on demand from membrane phospholipids, primarily by the enzymes diacylglycerol lipase alpha and beta (DAGLα, DAGLβ) [3].
- Degradation: broken down mainly by monoacylglycerol lipase (MAGL), with smaller contributions from ABHD6 and ABHD12 [3][4].
- Receptor activity: a full agonist at both CB1 and CB2 receptors. 2-AG is present in the brain at concentrations roughly 200 times higher than anandamide and is considered the principal endogenous CB1 agonist [4] Strong evidence.
Unlike THC, which is a partial agonist that lingers, 2-AG is made and destroyed rapidly — it's a short-range, on-demand messenger, not a circulating hormone.
Where it's found
2-AG is produced throughout the central and peripheral nervous system and in immune tissues. The highest concentrations are in the brain, where it functions as a retrograde neurotransmitter: released from postsynaptic neurons, it travels backward across the synapse to activate presynaptic CB1 receptors and dampen further neurotransmitter release [3][4] Strong evidence.
It is also detectable in plasma, breast milk, and various peripheral tissues. Trace amounts have been reported in some foods, but dietary 2-AG is not thought to contribute meaningfully to endocannabinoid tone — the molecule is synthesized locally where and when it's needed.
2-AG is not found in the cannabis plant. Cannabis produces phytocannabinoids (THC, CBD, CBG, etc.) and terpenes; 2-AG is exclusively an animal molecule.
Why it matters for cannabis
When you consume THC, it binds the same CB1 receptors that 2-AG normally activates. The difference is that THC is a partial agonist with a long half-life and is distributed systemically — so instead of brief, local signaling, you get diffuse, prolonged receptor activation across the whole brain. That mismatch is a reasonable mechanistic explanation for both the desirable effects (euphoria, appetite, analgesia) and the unwanted ones (anxiety, memory disruption, tolerance) [4][5] Strong evidence.
MAGL inhibitors — drugs that block the enzyme breaking down 2-AG, thereby raising endogenous 2-AG levels — have been studied as a way to harness CB1 signaling without administering THC. In rodents, MAGL inhibition produces analgesic and anti-anxiety effects but, with chronic dosing, also causes CB1 desensitization and tolerance similar to chronic THC exposure [6][evidence:strong in animals, no approved human therapies yet].
CBD does not directly bind CB1 or CB2 with meaningful affinity, but some evidence suggests it can indirectly modulate endocannabinoid tone, including 2-AG and anandamide levels, through effects on degrading enzymes and reuptake [evidence:weak in humans].
What we don't know
Endocannabinoid biology in humans is still being mapped. Open questions include:
- Whether circulating 2-AG levels in blood meaningfully reflect brain endocannabinoid tone (probably not, but used as a proxy in many clinical studies) Disputed.
- How chronic cannabis use reshapes the 2-AG / MAGL / CB1 system long-term in humans, and whether those changes fully reverse after abstinence Weak / limited.
- Whether 'clinical endocannabinoid deficiency' — a hypothesis that low endocannabinoid tone underlies conditions like migraine, fibromyalgia, and IBS — is a real, measurable syndrome or a popular framework awaiting better evidence [7] Disputed.
If you see a product or influencer claiming to 'boost your 2-AG' through a supplement, exercise, or specific cannabis strain, treat that claim skeptically. The science of deliberately modulating 2-AG in humans is still pre-clinical or early-clinical for almost every application.
Related molecules
If you're exploring endocannabinoid biology, the most relevant related entries are:
- Anandamide (AEA) — the other major endocannabinoid; named from the Sanskrit ananda (bliss).
- Arachidonic acid — the fatty acid building block of both 2-AG and anandamide.
- CB1 receptor and CB2 receptor — the targets.
- THC — the phytocannabinoid that mimics 2-AG at CB1.
- CBD — a phytocannabinoid that interacts with the endocannabinoid system indirectly.
For actual cannabis terpenes, see Myrcene, Limonene, Pinene, Caryophyllene, and Linalool.
Sources
- Peer-reviewed Mechoulam, R., Ben-Shabat, S., Hanus, L., et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.
- Peer-reviewed Sugiura, T., Kondo, S., Sukagawa, A., et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications, 215(1), 89–97.
- Peer-reviewed Murataeva, N., Straiker, A., & Mackie, K. (2014). Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. British Journal of Pharmacology, 171(6), 1379–1391.
- Peer-reviewed Lu, H.-C., & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516–525.
- Peer-reviewed Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215.
- Peer-reviewed Schlosburg, J. E., Blankman, J. L., Long, J. Z., et al. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nature Neuroscience, 13(9), 1113–1119.
- Peer-reviewed Russo, E. B. (2016). Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, 1(1), 154–165.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Myrcene — The most common monoterpene in cannabis, blamed and credited for a lot of things it probab...